What You Should Know:
- Biotia, a company fighting infectious diseases powered by genomics and artificial intelligence (AI), has raised an oversubscribed $8 million Series A round led by OCA Ventures.
- OCA, a veteran early-stage venture firm operating from Chicago and Palo Alto was joined by other key investors including Continuum Health Ventures, Phoenix Venture Partners, SeedtoB Capital, SK Square Americas, Digital-Dx Ventures, and others. Prior Seed round investors include Falcon II
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Using AI to Match Patients with Clinical Trials for Proactive Treatment
We are entering a new era of patient treatment options thanks to cutting-edge technologies that are changing the way life science companies approach and execute pharmaceutical research. One of the more significant solutions that support the faster and more efficient development of new pharmaceutical products – such as the COVID-19 vaccine, which was developed faster than any other vaccine in history – is artificial intelligence (AI)-driven data analysis. Thanks to modern life science technology
Read More
Avenda Health Receives FDA Exemption for AI-Enabled Prostate Cancer Therapy
What You Should Know:
- Avenda Health, an AI healthcare company creating the future of prostate cancer care, has received FDA Investigational Device Exemption (IDE) for its FocalPoint ablation system. The IDE will allow the technology, powered by iQuest, to be used in a randomized control trial to show superiority over the standard of care for the treatment of prostate cancer.
- FocalPoint is Avenda Health’s focal laser ablation system designed to treat localized prostate cancer
Read More
H1 Launches AI-Powered and Evidence-Based Interactions
What You Should Know:
- H1, launches an update to its flagship product, HCP Universe, the daily resource for global medical affairs and medical science liaison (MSL) teams.
- New features include a mobile app, Next-gen Smart Search capabilities built on an expansive knowledge graph, out-of-the-box insights tailored to inform MSL and Headquarter decisioning, and AI-powered notifications to improve and accelerate quality HCP engagement.
Establishing AI-Driven Efficient Workflows
H1 is
Read More
Astellas Pharma Selects Verizon to Transform Global Network
What You Should Know:
- Verizon Business has announced that it has been selected to build and manage Astellas Pharma Inc’s (Astellas) global network infrastructure.
- Today’s announcement builds on the company’s network-as-a-service foundation and supports its private networks, mobile edge compute and business solutions vectors of growth.
The Japanese multinational pharma company, one of the 30 biggest pharmaceutical companies in the world by revenue in 2022, is looking to
Read More
Healthcare Companies on the Stock Market
Good healthcare and the financial sector cannot be separated entirely, even when their base motivations lie in different directions. While the medical sector should focus more on the health of the patients instead of consumerism, a good amount of capital is needed to ensure a functional system.
Naturally, we can find healthcare companies on the stock market. Considering the continuous need for health care, that is not tied to market crashes the way other stocks are, this is a great chance for
Read More
H1 & Lokavant Partner to Power Next-Gen Clinical Trials
What You Should Know:
- H1and Lokavant today announced an extensive data-and-analytics collaboration to bring enhanced automated intelligence to drug development
- As part of the bi-directional partnership, Lokavant will provide performance data on global trial sites and principal investigators from thousands of studies to supplement H1’s existing Trial Landscape clinical trial repository.
Integrating Clinical Trial Data Sources to Intelligence Platforms
Lokavant is a clinical
Read More
How Medical Researchers Can Leverage Tech to Help Streamline Biospecimen Matchmaking and Procurement
Many medical advancements – from life-saving vaccines and treatments to new diagnostic tests like liquid biopsies – are built on research that involves human biospecimens. Biofluids, tissue and cells are indispensable resources for the medical researcher, yet the process of sourcing these biospecimens can be woefully frustrating and inefficient. These challenges can have a direct, negative impact on the pace of discovery, creating urgency for improved access to the biospecimens researchers need
Read More
NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers
What You Should Know:
- NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, and NeuraLight, a company developing objective and sensitive biomarkers for neurological disorders, today announced a collaboration to advance the science of digital biomarkers in the detection and monitoring of neurological diseases including amyotrophic lateral sclerosis (ALS).
- This agreement marks NeuraLight’s first clinical trial and comes on the heels of
Read More
Syapse Raises $35M to Expand Learning Health Network
What You Should Know:
- Syapse raises $35M led by an affiliate of Innovatus Capital Partners, LLC (Innovatus)to tackle the challenge of understanding, preventing, and treating complex cancers.
- The investment will allow Syapse to expand its artificial intelligence and machine learning capabilities, making it more efficient to uncover meaningful insights from real-world oncology data.
Syapse, a San Francisco, CA-based real-world evidence company accelerating the
Read More
